PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.92%
Both companies show declining cash positions (-42.92% vs TRVN's -49.87%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-42.83%
Below half of TRVN's 48.02%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.38%
Below half of TRVN's 47.06%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.44%
1.25-1.5x TRVN's -6.85%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.57%
1.25-1.5x TRVN's -5.37%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
Below half of TRVN's 46.49%. Michael Burry sees a potential red flag for stagnation or capital shortage.
31.92%
Above 1.5x TRVN's 11.61%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.79%
Less than half of TRVN's 4451.31%. David Dodd sees fewer expansions in other current obligations.
-7.19%
Similar yoy to TRVN's -7.50%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.19%
1.1-1.25x TRVN's -5.80%. Bill Ackman questions if the firm is incurring more total obligations than competitor.
1.19%
Less than half of TRVN's 48.77%. David Dodd sees fewer share issuances vs. competitor.
-6.33%
0.5-0.75x TRVN's -11.20%. Martin Whitman is wary of weaker retention or lower profitability.
-55.74%
Less than half of TRVN's 99.97%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-181.05%
Below half TRVN's 54.38%. Michael Burry sees potential underperformance in building shareholder capital.
-39.92%
Below half TRVN's 46.49%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.34%
Similar yoy changes to TRVN's 51.16%. Walter Schloss sees parallel net leverage strategies.